Sumitomo Pharma Co., Ltd.
4506.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | ¥38,490,000 | ¥20,453,000 | ¥23,116,000 | ¥85,393,000 |
| Short-Term Investments | ¥0 | ¥0 | ¥16,840,000 | ¥0 |
| Receivables | ¥127,263,000 | ¥86,131,000 | ¥74,840,000 | ¥97,259,000 |
| Inventory | ¥82,755,000 | ¥89,751,000 | ¥94,222,000 | ¥107,426,000 |
| Other Curr. Assets | ¥22,600,000 | ¥60,383,000 | ¥44,150,000 | ¥46,546,000 |
| Total Curr. Assets | ¥271,108,000 | ¥256,718,000 | ¥253,168,000 | ¥333,688,000 |
| Property Plant & Equip (Net) | ¥44,939,000 | ¥46,103,000 | ¥46,648,000 | ¥52,613,000 |
| Goodwill | ¥196,457,000 | ¥191,175,000 | ¥197,406,000 | ¥208,787,000 |
| Intangibles | ¥166,510,000 | ¥164,726,000 | ¥172,509,000 | ¥194,484,000 |
| Long-Term Investments | ¥82,884,000 | ¥58,270,000 | ¥56,501,000 | ¥45,342,000 |
| Tax Assets | ¥464,000 | ¥502,000 | ¥534,000 | ¥0 |
| Other NC Assets | ¥16,042,000 | ¥15,839,000 | ¥15,838,000 | ¥17,201,000 |
| Total NC Assets | ¥507,296,000 | ¥476,615,000 | ¥489,436,000 | ¥518,427,000 |
| Other Assets | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Assets | ¥778,404,000 | ¥733,333,000 | ¥742,604,000 | ¥852,115,000 |
| Liabilities | – | – | – | – |
| Payables | ¥42,046,000 | ¥39,308,000 | ¥38,544,000 | ¥49,278,000 |
| Short-Term Debt | ¥4,000,000 | ¥50,188,000 | ¥46,440,000 | ¥254,960,000 |
| Tax Payable | ¥0 | ¥0 | ¥1,577,000 | ¥0 |
| Deferred Revenue | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Curr. Liab. | ¥148,595,000 | ¥141,189,000 | ¥154,042,000 | ¥195,101,000 |
| Total Curr. Liab. | ¥199,029,000 | ¥231,687,000 | ¥240,603,000 | ¥499,339,000 |
| LT Debt | ¥258,850,000 | ¥259,057,000 | ¥258,982,000 | ¥119,463,000 |
| Deferred Rev, NC | ¥0 | ¥0 | ¥0 | ¥0 |
| Deferred Tax Liab, NC | ¥14,199,000 | ¥25,892,000 | ¥26,550,000 | ¥18,426,000 |
| Other NC Liab. | ¥40,738,000 | ¥40,464,000 | ¥41,520,000 | ¥48,772,000 |
| Total NC Liab. | ¥313,787,000 | ¥325,413,000 | ¥332,522,000 | ¥186,661,000 |
| Other Liabilities | ¥0 | ¥0 | ¥0 | ¥0 |
| Cap. Leases | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Liabilities | ¥512,816,000 | ¥557,100,000 | ¥573,125,000 | ¥686,000,000 |
| Equity | – | – | – | – |
| Pref Stock | ¥0 | ¥0 | ¥0 | ¥0 |
| Common Stock | ¥22,400,000 | ¥22,400,000 | ¥22,400,000 | ¥22,400,000 |
| Retained Earnings | ¥147,516,000 | ¥57,924,000 | ¥46,784,000 | ¥41,601,000 |
| AOCI | ¥96,354,000 | ¥96,591,000 | ¥100,977,000 | ¥102,796,000 |
| Other Equity | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Equity | ¥265,588,000 | ¥176,233,000 | ¥169,479,000 | ¥166,115,000 |
| Supplemental Information | – | – | – | – |
| Minority Interest | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Liab. & Tot. Equity | ¥778,404,000 | ¥733,333,000 | ¥742,604,000 | ¥852,115,000 |
| Net Debt | ¥224,360,000 | ¥288,792,000 | ¥282,306,000 | ¥289,030,000 |